GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » EV-to-EBIT

CureVac NV (CureVac NV) EV-to-EBIT : -0.20 (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CureVac NV's Enterprise Value is $62.03 Mil. CureVac NV's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-314.84 Mil. Therefore, CureVac NV's EV-to-EBIT for today is -0.20.

The historical rank and industry rank for CureVac NV's EV-to-EBIT or its related term are showing as below:

CVAC' s EV-to-EBIT Range Over the Past 10 Years
Min: -187.53   Med: -7.1   Max: -0.19
Current: -0.2

During the past 5 years, the highest EV-to-EBIT of CureVac NV was -0.19. The lowest was -187.53. And the median was -7.10.

CVAC's EV-to-EBIT is ranked worse than
100% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs CVAC: -0.20

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CureVac NV's Enterprise Value for the quarter that ended in Sep. 2023 was $1,075.31 Mil. CureVac NV's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-314.84 Mil. CureVac NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -29.28%.


CureVac NV EV-to-EBIT Historical Data

The historical data trend for CureVac NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV EV-to-EBIT Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
- - -99.59 -12.17 -2.65

CureVac NV Quarterly Data
Dec18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.94 -2.65 -3.10 -5.70 -3.42

Competitive Comparison of CureVac NV's EV-to-EBIT

For the Biotechnology subindustry, CureVac NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CureVac NV's EV-to-EBIT falls into.



CureVac NV EV-to-EBIT Calculation

CureVac NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=62.032/-314.842
=-0.20

CureVac NV's current Enterprise Value is $62.03 Mil.
CureVac NV's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-314.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (NAS:CVAC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CureVac NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-314.842/1075.30792
=-29.28 %

CureVac NV's Enterprise Value for the quarter that ended in Sep. 2023 was $1,075.31 Mil.
CureVac NV's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-314.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CureVac NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.